Efficacy and tolerability of fentiazac in rheumatoid arthritis: Double-blind study versus indomethacin

Abstract

A double-blind trial was carried out in 40 patients with classic or definite rheumatoid arthritis to compare the efficacy and tolerability of fentiazac (300 mg per day) with that of indomethacin (75 mg per day) over a 3-week treatment period. The results showed that there were significant improvements in painful and swollen joints, duration of morning stiffness and grip strength in both groups at the end of the trial. Overall response to treatment, as assessed by the investigator and taking into account the patients' opinions, was considered to be very good or good in 78.9% of those receiving fentiazac and in 73.6% of those receiving indomethacin. Although the differences were not statistically significant, there was a trend for greater and continued improvement in the fentiazac group in all of the parameters evaluated. Few side-effects were reported and both drugs appeared to be well tolerated. No clinically relevant changes were noted in routine laboratory investigations.